Brief: TG Therapeutics, Neuraxpharm Announce Ex-US Commercialization Agreement For BRIUMVI

TG Therapeutics

01/08/2023 12:07

Aug 1 (Reuters) - TG Therapeutics Inc  TGTX.O :
    * TG THERAPEUTICS AND NEURAXPHARM ANNOUNCE EX-US
COMMERCIALIZATION
AGREEMENT FOR BRIUMVI® (UBLITUXIMAB-XIIY)
    * TG THERAPEUTICS INC - TOTAL DEAL SIZE OF ABOUT $650M,
INCLUDING
OVER $150M IN UPFRONT AND NEAR-TERM MILESTONES
    * TG THERAPEUTICS INC - IN ADDITION, TG WILL RECEIVE TIERED
DOUBLE-DIGIT ROYALTIES ON NET PRODUCT SALES UP TO 30%
    * TG THERAPEUTICS - RETAINS OPTION TO BUY BACK ALL RIGHTS
UNDER
COMMERCIALIZATION AGREEMENT FOR A PERIOD OF 2 YRS IN EVENT OF A
CHANGE IN CONTROL OF TG

Source text for Eikon:  ID:nGNX4Vsf2H 
Further company coverage:  TGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))